Discover Accurate and Flexible Prostate Cancer Risk Prediction.

Now Available for At-Home Sample Collection. Covered by Medicare. 

This non-DRE urine test delivers best-in-class precision in identifying patients at low risk for clinically significant prostate cancer, supporting informed decisions. It’s available for both at-home and in-office collection.

Client Services:
(888) 978-8677
8 a.m.-8 p.m. ET
Monday-Friday

Chat icon

Live Chat
Chat with our Client Services team.

Trusted by providers. No DRE required.

Let’s explore how MyProstateScore 2.0 fits into your practice and elevate your approach to PSA risk stratification.

Complete the form to connect with a Lynx Dx representative, who will:

  • review performance data
  • help set up your provider account
  • and guide you through the steps to begin offering MyProstateScore 2.0.

MyProstateScore 2.0 (MPS2)

MyProstateScore 2.0 (MPS2) was built on a cohort-specific algorithm to optimize diagnostic accuracy and provide validated and objective performance for patients considering an initial or repeat prostate biopsy.

Its 18 biomarkers are the most comprehensive and demonstrate the most extensive performance characteristics of any test on the market, with the option to enhance the analysis with clinical factors.

With the new flexibility to collect samples at home, paired with Medicare coverage, MPS2 fits seamlessly into your workflow while enhancing patient experience.